Navigation Links
Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain

Post-Treatment Segment of Elagolix Petal Study Confirms Previous Positive Findings on Efficacy and Safety

Neurocrine to Present These Additional Study Results at Deutsche Bank 34th Annual Healthcare Conference Today at 5:05pm Eastern Time

SAN DIEGO, May 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced additional positive safety and efficacy results from its Phase IIb clinical trial known as the Petal Study (603 study) using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. The Petal Study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups; elagolix 150 mg once daily, elagolix 75 mg twice daily, or depo-subQ provera 104(TM) (DMPA) for six months of treatment followed by six months of no treatment. Database lock and unblinding of the full 48 week data set has provided more insight on the clinical benefits and safety profile of elagolix for the treatment of pain associated with endometriosis.

"As expected, elagolix did not induce significant bone loss over the six-month follow up phase of the Petal Study," said Chris O'Brien, MD, Neurocrine's Chief Medical Officer. "Additionally, we are seeing for the first time an oral GnRH antagonist with a rapid and sustained symptom reduction during treatment that also provides a statistically and clinically significant improvement in symptoms which persists after discontinuation of therapy. These are intriguing results and raise the possibility that elagolix treatment may have a disease modifying effect."

Key findings include the following:

Bone Safety: As previously reported, the primary endpoint of the Petal Study, impact on bone mineral density (BMD), was met at Week 24. Neurocrine now has confirmation of a favorable bone safety profile at Week 48 with no cumulative reduction in BMD evident. Mean change from baseline for elagolix 150 mg qd remained at close to 0% at Week 48, with n-telopeptide values remained close to a mean of 10 nM BCE (normal range 6-19 nM BCE for this age group).

Pain reduction: Sustained improvement at Week 48 compared to baseline was demonstrated (p<0.0001) in the mean Composite Pelvic Signs and Symptoms Score (CPSSS) such that many subjects would no longer qualify for enrollment (a requirement of CPSSS greater than or equal to 6 at Screening). The findings were nearly identical when comparing the ITT population (n=252 randomized) and the "completers" (n=131 subjects who completed the no-treatment out to Week 48) providing confirmation of the robust nature of this improvement. The "responder rate" on the dysmenorrhea component of the CPSSS at Week 24 was 77% and at Week 48 was 64% based on the definition of an improvement of greater than or equal to 1 point (elagolix 150 mg qd). As menstruation returned following discontinuation of elagolix, dysmenorrhea symptoms become more common but did not reach baseline severity. At Week 48 the mean scores for all treatment groups remained improved (p<0.0001) and are comparable among treatment groups. The "responder rate" on the Non-Menstrual Pelvic Pain component of the CPSSS at Week 24 was 86% and at Week 48 was 67% based on the definition of an improvement of greater than or equal to 1. The mean scores for the treatment groups also did not return to baseline severity after discontinuation of treatment and remained statistically significantly improved at Week 48 (p<0.0001) (elagolix 150 mg qd).

Quality of Life: The Endometriosis Health Profile (EHP-5) assessed the impact of endometriosis symptoms on five core domains. At baseline, approximately 80% of subjects reported that they suffered difficulties across all domains "sometimes," "often" or "always." After treatment this shifted dramatically such that 60-80% of subjects said "never" or "rarely" to these same EHP-5 questions. Equally notable is the observation that much of this improvement was sustained post-treatment.

Estradiol and Ovulation: The previously reported pharmacodynamic effect of elagolix was confirmed. Median estradiol values were maintained in the low baseline range while on treatment and, most importantly, were not lowered to values that would be associated with hot flashes or clinically significant bone loss. As reported, Week 24 median estradiol was 47 pg/ml for elagolix once daily and 29 pg/ml for elagolix twice daily. At Week 48, the median values for the groups were normal at 80 pg/ml and 84 pg/ml, respectively. The mean time to ovulation post-treatment was 24 days for women who had been randomized to elagolix and >90% of subjects had evidence of ovulation within 4 weeks of stopping. Prolonged suppression of ovulation was documented, even out to Week 48 in the DMPA subjects who also reported frequent spotting and irregular vaginal bleeding.

Safety and Tolerability: Assessment of vital signs, physical examination, electrocardiogram, and clinical laboratory tests did not reveal any safety concerns. Adverse events that were reported were generally mild and transient in nature and not usually associated with study discontinuation. The most common adverse events in this trial were consistent with what we have observed in the other elagolix trials including headache (approximately 20% of subjects reported 1 or more headaches during the 6 months of treatment) and nausea (approximately 15% of subjects reported 1 or more episode of nausea). The most common reason for premature discontinuation from the study was withdrawal of consent (i.e., subject moved, work conflict, etc). Seven subjects withdrew from the study with excessive, prolonged or breakthrough bleeding attributed to DMPA. The reporting of adverse events decreased by 50% in the post treatment period; no pattern of specific safety concerns due to elagolix have been identified. Hot flashes were reported by approximately 40% of subjects during the screening period (mean 0.4 per day) and 40% during the treatment period (mean 0.7 per day). Approximately 25% of subjects reported hot flashes during the post-treatment period (mean 0.4 per day). No pattern of excessive estradiol suppression was detected.

The twelve-month data from the Petal Study will be presented at various upcoming scientific meetings and in manuscript form. The bone data from the Petal Study are scheduled for presentation at the Endocrine Society Meeting in Washington, DC on June 12, 2009. The Petal Study safety and efficacy data have been submitted for the American Society for Reproductive Medicine (ASRM) meeting scheduled this fall in Atlanta. A subset of the Petal Study subjects will return for Week 72 DXA scans and clinical assessments to satisfy earlier arrangements made in consultation with the FDA.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine related diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include, but are not limited to, risk that the Company's elagolix Phase II clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to later stage clinical trials; risk associated with the Company's dependence on corporate collaborators for development, commercial manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2008 and report on Form 10-Q for the quarter ended March 31, 2009. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
3. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
4. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
5. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
6. Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference
7. GNAX/AtlantaNAP Announces Newest Client, Health Information Designs
8. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
9. AMR Research Announces Final Agenda for Sold-Out Supply Chain Executive Conference
10. International Student Insurance Announces Website Redesign
11. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
Post Your Comments:
(Date:2/11/2016)... Orange City, FL (PRWEB) , ... February 11, ... ... has announced the commencement of a master charity program created to assist the ... every 60 days, working closely with nonprofit organizations and community leaders. Their hope ...
(Date:2/11/2016)... ... 11, 2016 , ... Dickinson Insurance & Financial Services continues their commitment to ... support of a local boy named Barrett, who has been fighting ALL leukemia for ... rally support for, all local families dealing with childhood cancer. Information on how to ...
(Date:2/11/2016)... City, Utah (PRWEB) , ... February 11, 2016 ... ... wireless microFET medical dynamometers and ergoFET force gauges used in physical therapy, occupational ... Rehab Strength Indicator sensor for resistance cord exercise and therapy, introduces its new ...
(Date:2/11/2016)... AZ (PRWEB) , ... February 11, 2016 , ... As ... with support of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to ... according to Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support ...
(Date:2/10/2016)... ... 10, 2016 , ... LaserShip, a regional parcel carrier that services the eastern ... Michigan last Friday in order to aid in the Flint water crisis. In 2014, ... facility located in Clio, only 15 miles away from Flint. , “We have deep ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016  Community pharmacists can help improve medication adherence ... through a custom-built medication synchronization program, Cardinal Health MedSync ... at Schieber Family Pharmacy in ... of patients enrolled in this medication synchronization program, which ... for the patient, and it,s a win for us ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016 ... the use of the iFuse Implant System, a ... for certain disorders of the sacroiliac (SI) joint, ... the cost benefits of MIS SI joint fusion ... due to degenerative sacroiliitis or SI joint disruption.  ...
(Date:2/11/2016)... ENGLEWOOD, Colo. , Feb. 11, 2016  Ampio ... February 10, 2016, it entered into a Controlled Equity ... Co. ("Cantor Fitzgerald"). Michael Macaluso , Chairman ... we stated that we are not currently raising money ... through 2016 and into 2017 and still complete all ...
Breaking Medicine Technology: